70 related articles for article (PubMed ID: 34658297)
1. Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.
Pandey K; Park N; Park KS; Hur J; Cho YB; Kang M; An HJ; Kim S; Hwang S; Moon YW
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260316
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells.
Conroy LR; Lorkiewicz P; He L; Yin X; Zhang X; Rai SN; Clem BF
Cancer Cell Int; 2020; 20():280. PubMed ID: 32624705
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of Rb phosphorylation in atherosclerosis.
Hiesinger W; Cohen JE; Atluri P
Cell Cycle; 2014; 13(3):352. PubMed ID: 24346501
[No Abstract] [Full Text] [Related]
4. Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation.
Jost T; Heinzerling L; Fietkau R; Hecht M; Distel LV
Front Oncol; 2021; 11():740002. PubMed ID: 34722291
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data.
Masuda N; Kosaka N; Iwata H; Toi M
Int J Clin Oncol; 2021 Dec; 26(12):2179-2193. PubMed ID: 34698970
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.
Marouille AL; Petit E; Kaderbhaï C; Desmoulins I; Hennequin A; Mayeur D; Fumet JD; Ladoire S; Tharin Z; Ayati S; Ilie S; Royer B; Schmitt A
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34684001
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of Natural Products in Cancer Treatment.
Ghosh S; Das SK; Sinha K; Ghosh B; Sen K; Ghosh N; Sil PC
Arch Toxicol; 2024 May; ():. PubMed ID: 38795134
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibitors in lung cancer: current practice and future directions.
Lv S; Yang J; Lin J; Huang X; Zhao H; Zhao C; Yang L
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38355149
[TBL] [Abstract][Full Text] [Related]
9. MiR-124-3p mediates gastric cancer cell ferroptosis induced by an anti-cancer drug polyphyllin I.
Zheng F; Bi JC; Wei YY; Wang Y; Zhang Q; Liang CL; Wu J; Dai Z
Front Pharmacol; 2023; 14():1285799. PubMed ID: 38027010
[No Abstract] [Full Text] [Related]
10. Polyphyllin I suppresses the gastric cancer growth by promoting cancer cell ferroptosis.
Zheng F; Wang Y; Zhang Q; Chen Q; Liang CL; Liu H; Qiu F; Chen Y; Huang H; Lu W; Dai Z
Front Pharmacol; 2023; 14():1145407. PubMed ID: 37081971
[No Abstract] [Full Text] [Related]
11. Identification and vitro verification of the potential drug targets of active ingredients of Chonglou in the treatment of lung adenocarcinoma based on EMT-related genes.
Zhao F; Zhao P; Chang J; Sun X; Ma X; Shi B; Yin M; Wang Y; Yang Y
Front Genet; 2023; 14():1112671. PubMed ID: 36824434
[TBL] [Abstract][Full Text] [Related]
12. Polyphyllin I Effects
Sun AM; Wang YX; Hu GX; Li L; Wang RR
Evid Based Complement Alternat Med; 2023; 2023():5645500. PubMed ID: 36726525
[No Abstract] [Full Text] [Related]
13. A review on the role of cyclin dependent kinases in cancers.
Ghafouri-Fard S; Khoshbakht T; Hussen BM; Dong P; Gassler N; Taheri M; Baniahmad A; Dilmaghani NA
Cancer Cell Int; 2022 Oct; 22(1):325. PubMed ID: 36266723
[TBL] [Abstract][Full Text] [Related]
14. PRIM2 Promotes Cell Cycle and Tumor Progression in p53-Mutant Lung Cancer.
Wang T; Tang T; Jiang Y; He T; Qi L; Chang H; Qiao Y; Sun M; Shan C; Zhu X; Liu J; Wang J
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884433
[TBL] [Abstract][Full Text] [Related]
15. Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway
Shen Z; Wang J; Ke K; Chen R; Zuo A; Zhang R; Wan W; Xie X; Li X; Song N; Fu H; Zhang Z; Cai E; Shen J; Zhang Q; Shi X
Cell Cycle; 2021 Dec; 20(23):2494-2506. PubMed ID: 34658297
[TBL] [Abstract][Full Text] [Related]
16. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
17. Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma.
Chen T; Liu L; Zou Y; Hu X; Zhang W; Zhou T; Luo X; Fu W; Xu J
Cancer Biol Med; 2021 Feb; 18(1):227-244. PubMed ID: 33628597
[TBL] [Abstract][Full Text] [Related]
18. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
